The meningococcal vaccine is a group of vaccines that protect against bacterial meningitis and bloodstream infections caused by Neisseria meningitidis, a bacterium responsible for some of the most dangerous infections in adolescents and young adults. Six meningococcal vaccines are currently available in the United States, each targeting different strains of the bacterium. Most teens receive their first dose at age 11 or 12, with a booster at 16.
What Meningococcal Disease Does
Neisseria meningitidis bacteria can invade the lining of the brain and spinal cord (causing meningitis) or enter the bloodstream (causing septicemia). Both conditions escalate fast, sometimes progressing from mild flu-like symptoms to life-threatening illness within hours. Even with treatment, meningococcal disease kills about 10 to 15 percent of those infected, and survivors can face lasting complications like hearing loss, brain damage, or limb amputations.
Five serogroups, essentially strains labeled A, B, C, W, and Y, cause nearly all human disease. Which strains dominate depends on geography. In Europe, the Americas, and Australia, serogroups B, C, W, and Y account for the large majority of cases. In sub-Saharan Africa’s “meningitis belt,” serogroup A historically drove outbreaks, though widespread vaccination there has shifted the burden toward serogroups C and W.
Types of Meningococcal Vaccines
The vaccines fall into three categories based on which serogroups they cover:
- MenACWY (quadrivalent): Protects against serogroups A, C, W, and Y. This is the one most adolescents receive as part of the routine schedule.
- MenB: Protects specifically against serogroup B, which the quadrivalent vaccine does not cover. Serogroup B is responsible for a significant share of cases in the U.S. and Europe, particularly among teens and young adults.
- MenABCWY (pentavalent): A newer combination that covers all five major serogroups (A, B, C, W, and Y) in a single vaccine series. Penbraya, the first of these approved by the FDA, is indicated for people ages 10 through 25. A second pentavalent option, Penmenvy, is also available. These vaccines simplify the process by combining coverage that previously required two separate vaccine series.
Who Should Get Vaccinated
The routine schedule calls for two doses of a MenACWY vaccine: the first at age 11 or 12 and a booster at 16. The booster is timed so that protection is strongest during the late teen years, when the risk of meningococcal disease peaks, especially for those entering college dorms, military barracks, or other close-living situations.
MenB vaccination follows a different path. Rather than being universally required, it’s typically offered to teens and young adults between 16 and 23 as a shared clinical decision, meaning you and your provider weigh the benefits together. The pentavalent vaccines now offer an option to cover both MenACWY and MenB serogroups in a single series, which may reduce the total number of shots needed.
People at Higher Risk
Certain medical conditions significantly raise the risk of meningococcal disease and change the vaccination timeline. People with the following conditions are recommended to receive both MenACWY and MenB vaccines, often starting earlier and with additional doses:
- Complement deficiency: A weakened part of the immune system that normally helps kill bacteria directly. This includes both inherited deficiencies and those caused by medications that block complement activity.
- Functional or anatomic asplenia: This includes people who have had their spleen removed or whose spleen doesn’t work properly, as in sickle cell disease. The spleen plays a key role in filtering bacteria from the blood.
- HIV: Recommended for MenACWY vaccination due to increased susceptibility.
Microbiologists and lab workers who routinely handle the bacteria, along with travelers to regions with active outbreaks, also have specific vaccination recommendations.
How Well the Vaccines Work
Meningococcal vaccines are highly effective. In a study of young children who received the full MenB series, vaccine effectiveness against serogroup B invasive disease reached roughly 95 percent. Even partially vaccinated children showed effectiveness above 91 percent. These numbers are reassuring, though they come from studies in children; effectiveness in adolescents and adults is expected to be comparable or higher, since older immune systems tend to respond more robustly to vaccines.
One important caveat is that protection does not last forever. After a primary vaccination series, the percentage of people maintaining protective antibody levels drops over the following six years. A booster dose given at age 7 or older appears to extend protection for at least three years, and likely longer. This waning is exactly why the routine schedule includes that second MenACWY dose at 16: it refreshes immunity heading into the highest-risk years.
Side Effects
Meningococcal vaccines cause the same general side effects as most other vaccines, and the vast majority are mild and short-lived. The specific profile varies by vaccine type.
For the MenACWY vaccines, the most common reactions include injection site pain (reported by 35 to 45 percent of adolescents), muscle aches (27 to 35 percent), headache (27 to 30 percent), and general fatigue or malaise (19 to 26 percent). Injection site redness occurs in about 14 to 20 percent of recipients. Fainting after the shot happens in roughly 9 percent of cases with one formulation, which is why providers often ask you to sit for 15 minutes afterward.
MenB vaccines tend to cause more noticeable soreness. Pain at the injection site occurs in 83 percent or more of recipients, with fatigue, headache, and muscle pain each affecting at least 30 to 35 percent. The pentavalent MenABCWY vaccines have a similar profile: injection site pain in about 84 to 89 percent, fatigue in roughly half, and headache in 40 to 47 percent. These symptoms typically resolve within a day or two.
Serious allergic reactions are rare. The only firm contraindication for any meningococcal vaccine is a history of severe allergic reaction (anaphylaxis) to a previous dose or a known allergy to a specific vaccine component. Common misconceptions include the belief that a penicillin allergy or a family history of allergies prevents vaccination. Neither is a contraindication.
Pentavalent Vaccines: Covering All Five Serogroups
Until recently, getting full meningococcal coverage meant receiving two entirely separate vaccine series: one for serogroups A, C, W, and Y and another for serogroup B. The approval of pentavalent vaccines changes that equation. Penbraya, approved for individuals ages 10 through 25, combines protection against all five major serogroups. This is particularly relevant for teens and young adults who want comprehensive coverage without navigating two different vaccine schedules.
The pentavalent option doesn’t eliminate multiple shots entirely, since the series still requires more than one dose. But it consolidates what used to be separate products into a streamlined path, which may improve the chances that people actually complete the full series.